The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Razumova I.Yu.

Research Institute of Eye Diseases

Godzenko A.A.

Russian Medical Academy of Continuous Professional Education

Nonsteroidal anti-inflammatory drugs in the treatment of anterior uveitis associated with spondyloarthritis

Authors:

Razumova I.Yu., Godzenko A.A.

More about the authors

Journal: Russian Annals of Ophthalmology. 2020;136(6): 70‑77

DOI: 10.17116/oftalma202013606170

Read: 15897 times

Download PDF (RU)
Contact the author
Table of contents

NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN THE TREATMENT OF ANTERIOR UVEITIS ASSOCIATED WITH SPONDYLOARTHRITIS
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN THE TREATMENT OF ANTERIOR UVEITIS ASSOCIATED WITH SPONDYLOARTHRITIS

To cite this article:

Razumova IYu, Godzenko AA. Nonsteroidal anti-inflammatory drugs in the treatment of anterior uveitis associated with spondyloarthritis. Russian Annals of Ophthalmology. 2020;136(6):70‑77. (In Russ.)
https://doi.org/10.17116/oftalma202013606170

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Biomarkers in tear fluid in uveitis. Russian Annals of Ophthalmology. 2025;(4):88-95
Use of a fixed combination of diclofenac and orphenadrine (Neodolpasse) for postoperative analgesia after exte­nded gastrectomy with rese­ction of the lower third of the esophagus. P.A. Herzen Journal of Onco­logy. 2025;(2):52-56
Abstract:

Anterior uveitis (AU) is one of the common extraskeletal manifestations of spondyloarthritis (SpA). The course of AU in patients with SpA is characterized by frequent relapses. The article considers the question of local and systemic use of nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment and prevention of SpA-associated uveitis exacerbations.

Keywords:

uveitis
spondyloarthritis
nonsteroidal anti-inflammatory drugs

Authors:

Razumova I.Yu.

Research Institute of Eye Diseases

Godzenko A.A.

Russian Medical Academy of Continuous Professional Education

Received:

17.05.2020

Accepted:

02.06.2020

Close metadata

References:

  1. Erdes SF, Badokin VV, Bochkova AG, Bugrova OV, Godzenko AA, Dubikov AA i dr. On the terminology of spondyloarthritis. Nauchno-prakticheskaya revmatologiya. 2015; 53(6):657-660. (In Russ.). https://doi.org/10.14412/1995-4484-2015-657-660
  2. Khan MA. Update on Spondyloarthropathies. Ann Intern Med. 2002;136(12): 896-907.  https://doi.org/10.7326/0003-4819-136-12-200206180-00011
  3. Razumova IYu, Godzenko FF, Vorob’eva OK, Guseva IA. Uveitis in the spondyloarthritis patients and its association with HLA-B27 histocompatibility antigen: prospective study. Vestnik oftal’mologii.2016;132(4):4-9. (In Russ.). https://doi.org/10.17116/oftalma201613244-9
  4. Erdes SHF, Volnuhin EV, Galushko EA. Treatment in Patients with Ankylosing Spondylitis in the Real Clinical Practice of the Rheumatologist in Russia. Nauchno-practicheskaya Revmatologiya. 2013;511:15-20. (In Russ.).
  5. Vander Gruyssen B, Ribbens C, Boonen A, Mielants H, de Vlam K, Lenaerts J, Stenfeld S, Van den Bosch F, Dewulf L, Vastesaeger N. The epidemiology of ankylosing spondylitis and the commencement of anti- TNF therapy in daily. Rheumathology practice of the rheumatic diseases. 2007;66(8):1072-1077. https://doi.org/10.1136/ard.2006.064543
  6. Rossiiskie klinicheskie rekomendatsii. Revmatologiya. Pod red. Nasonova E.L. M.: Geotar-Media; 2017. (In Russ.).
  7. Feltkamp TEW, Ringrose J. Acute anterior uveitis and spondyloarthropathies. Current Opinion in Rheumatology. 1998;10(4):314-318. 
  8. Martin TM, Smith JR, Rosenbaum JT. Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies. Current Opinion in Rheumatology. 2002;14(4):337-341.  https://doi.org/10.1097/00002281-200207000-00001
  9. Feldtkeller E. Age at disease onset and delayed diagnosis of spondyloarthropathies. Z Reumatol. 1999;58(1):21-30.  https://doi.org/10.1007/s003930050149
  10. Rozenbaum ST. Caracterization of uveitis associated with spondyloarthritis. The Journal of rheumatology. 1989;16(6):792-796. 
  11. Budzinskaya MV, Shelankova AV, Plukhova AA, Nuriyeva NM, Sorokin AS. The Role of Steroids in the Management of Macular Edema from Retinal Vein Occlusion. Oftal’mologiya. 2019;16(1):95-101. (In Russ.). https://doi.org/10.18008/1816-5095-2019-1-95-101
  12. Strukov AI, Serov VV. Patologicheskaya anatomiya. M.: Medicina; 1995. (In Russ.).
  13. Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Topical Ocular Delivery of NSAIDs. AAPS.J. 2008;10(2):229-241.  https://doi.org/10.1208/s12248-008-9024-9
  14. Amico C, Yakimov M, Catania MV, Giuffrida R, Pistone M, Enea V. Differential expression of cyclooxidenase -1 and cyclooxigenase — 2 in the cornea during wound healing. Tissue Cell. 2004;36(1):1-12.  https://doi.org/10.1016/j.tice.2003.08.001
  15. Radi ZA, Render JA. The pathophysiologic role of cyclo-oxigenases in the eye. J Ocul Pharmacol Ther. 2008;24(2):141-151.  https://doi.org/10.1089/jop.2007.0078
  16. Ju WK, Neufeld AH. Cellular localization of cyclooxygenase -1 and cyclooxygenase-2 in the normal mouse, rat, and human retina. J Comp Neurol. 2002;452(4):392-399.  https://doi.org/10.1002/cne.10400
  17. Chin MS, Nagineni CN, Hooper LC, Detrick B, Hooks JJ. Cyclooxygenase-2 gene expression and regulation in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2001;42(10):2338-2346.
  18. Oka T, Shearer TR, Azuma M. Involvement of cyclooxigenase-2 in rat models of conjunctivitis. Curr Eye Res. 2004;29(1):27-34.  https://doi.org/10.1080/02713680490513164
  19. Chandrasekharan NV, Hu L, Lamar TRK, Natan K, Evanson K, Tomsik J, Elton TS, Simmons DL. COX-3, a cyclooxigenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. PNAS; 2002;19.  https://doi.org/10.1073/pnas.162468699
  20. Guex-Crosier Y. Non-steroidal anti-inflammatory drugs and ocular inflammation. Klin Monbl Augenheilkd. 2001;218(5):305-308.  https://doi.org/10.1055/s-2001-15886
  21. Park GY, Cristman JW. Nuclear factor Kappa B is a promising therapeutic target in inflammatory lung disease. Cur drug Targets. 2006;7(6):661-668. 
  22. Lee I, Jung W, Choi Y, Kim Y. The effects of steroids and nonsteroidal anti-inflammatory agents on proliferation of human ocular fibroblast. J Korean Ophthalmol Soc. 1999;40:1496-1502.
  23. Nowak J. Non-steroidal anti-inflammatory drugs (NSAIDs) in ophthalmology: pharmacological and clinical characteristics. Mil Pharm Med. 2012; 5(4):33-50. 
  24. Yousufzai SY, Zheng P, Abdel-Latif AA. Muscarinic stimulation of arachidonic acid release and prostaglandin synthesis in bovine ciliary muscle: prostaglandins induce cyclic AMP formation and muscul relaxation. Exp Eye Res. 1994;58(5):513-522.  https://doi.org/10.1006/exer.1994.1045
  25. Razumova IY, Vorob’eva OK, Godzenko AA. Diagnosis and treatment of HLA-B27 — associated uveitis. Vestnik oftal’mologii. 2009;125(3):15-18. (In Russ.).
  26. McChee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risk. Drugs Saf. 2002;25(1):33-55.  https://doi.org/10.2165/00002018-200225010-00004
  27. Flach AJ. Topical nonsteroidal anti-inflammatory drugs in ophthalmology. Int Ophthalmol Clin. 2002;42:1-11. 
  28. Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica. 2003;217:89-98.  https://doi.org/10.1159/000068563
  29. Roberts CW, Brennan KM. A comparison of topical diclofenac with prednisolone for postcataract inflammation. Arch Ophthal. 1995;113:725-727.  https://doi.org/10.1001/archopht.1995.01100060051031
  30. EL-Harazi SM, Ruiz RS, Feldman RM, Villanueva G, Chuang AZ. A randomized double — masked trial comparing ketorolac tromethamine 0.5%, diclofenac sodium 0.1%, and prednisolone acetate 1% in reducing post phacoemulsification flare and cells. Ophthalmic Surg Lasers. 1998;29:539-544. 
  31. Flach FJ. Nonsteroidal anti-inflammatory drugs. In: Tasman W, editor. Duane’s foundations of clinical ophthalmology. Philadelphia (PA): Lippincott; 1994.
  32. Wolf EJ, Braunstein A, Shih C, Braunstein RE. Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac. J Cataract Refract Surg. 2007;33(9): 1546-1549. https://doi.org/10.1016/j.jcrs.2007.05.018
  33. Heier JS, Topping TM, Baumann W, Dirks MS, Chern S. Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology. 2000;107:2034-2039. https://doi.org/10.1016/s0161-6420(00)00365-1
  34. Abdel-Latif AA. Regulation of arachidonate release, prostaglandin synthesis, and sphincter constriction in the mammalian iris-cyliary body. prog Clin Biol Res. 1989;312:53-72. 
  35. Mal’hanov VB, Shevchuk NE, Absalikova DK. Dynamics of interleukin 1-Beta and prostaglandin E2 with endogenous uveitis. Refraccionnaya hirurgiya i oftalmologiya. 2010;1:40-42. (In Russ.).
  36. Bucolo C, Marrazzo G, Platania CB, Romano GL, Drago F, Salomone S. Effects of topical indometacin, bromfenac and nepafenac on lipopolysaccharide-induced ocular inflammation. J Pharm Pharmacol. 2014;66(7):954-960.  https://doi.org/10.1111/jphp.12224
  37. Weber V, Kodjikian I, Kruse FE, Zagorski Z, Allaire CM. Efficacy and safety of indomethacin 0.1% eye drops compared with ketorolak 0.5% eye drops in the management of ocular inflammation after cataract surgery. Acta Ophthalmol. 2013;91(1):15-21. 
  38. Yavas GF, Oztürk F, Küsbeci T. Preoperative topical indomethacin to prevent pseudophakic cystoid edema. J Cataract Refract Surg. 2007;33(5):804-807.  https://doi.org/10.1016/j.jcrs.2007.01.033
  39. Allegri P, Murialdo U, Peri S, Carniglia R, Crivelli MG,et al. Randomized double blind, placebo-controlled clinical trail on the efficacy of 0.5% indomethacin eye drops in uveitic macular edema. Invest Ophthalmol vis Sci. 2014;55(3):1463-1470. https://doi.org/10.1167/iovs.13-13202
  40. Cho H, Wolf KJ, Wolf EJ. Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. Clin Ophthalmol. 2009;3:199-210.  https://doi.org/10.2147/opth.s4806
  41. Aleksandrova OI, Okolov IN, Khorolskaya YuI, Panova IE, Blinova MI. Influence of Nonsteroidal Anti-inflammatory Eye Drops on the Epithelium Cells of the Cornea and Conjunctiva in vitro. Oftal’mologiya. 2017;15(3):251-259. (In Russ.). https://doi.org/10.18008/1816-5095-2017-3-251-259
  42. Baranovski P, Karolewicz B, Gajda M, Pluta J. Ophthalmic Drug Dosage Forms: Characterisation and Research Methods. The ScientificWorld Journal. 2014. https://doi.org/10.1155/2014/861904
  43. Morozov VI. A gemato-ophthalmic barrier: structural and functional features. RMZ. Klinicheskaya oftal’mologiya. 2017;10(4):68-72. (In Russ.).
  44. Nasonov EL. Non-steroidal Anti-inflammatory Drugs: New Aspects of Application in Rheumatology and Cardiology. Russkii Medicinskii Zhurnal. 2003;11(23):1280-1284. (In Russ.).
  45. Karateev AE, Nasonov EL, Ivachkin VT, Martynov AI, Uachno NN, Arutyunov GP i dr. Rational Use of Nonsteroidal Anti-inflammatory Drugs. Clinical Guidelines. Nauchno-practicheskaya Revmatologiya. 2018;56(1):1-29. (In Russ.). https://doi.org/10.14412/1995-4484-2018-1-29
  46. Karateev AE, Erdes ShF. Use of nonsteroidal anti-inflammatory drags in case of ankylosing spondylitis long and persistenly! Terapevtisheskii arhiv. 2014;86(ІІ):123-127. (In Russ.).
  47. Zochling J,Van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC, et al. Non-steroidal anti-inflammatory drugs inhibit radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. EULAR. 2004; Abstracts, SP0077.
  48. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon JL, Spabraw I, Schlinker A, Bonilla G, Ruis-Sancho D, Fonseca F, et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol. 2003;30(6):1277-1279.
  49. Fiorelli VM, Bhat P, Foster CS. Nonsteroidal anti—inflammatory therapy and recurrent acute anterior uveitis. Ocul Immunol Inflamm. 2010; 18(2):116-120.  https://doi.org/10.3109/09273941003587558
  50. Schjerning Olsen AM, Gislason GH, McGettigan P, Gerds TA, Fosbol TL, Olesen JB, Sinden-Pedersen C, Staerk L, et al. Association of NSAID use with risk of bleeding and cfrdiovascular events in patients reseiving antithrombotic therapy after myocardial infarction. JAMA. 2015;313(8):805-814.  https://doi.org/10.1001/jama.2015.0809
  51. Moore A, Makinnson G, Li C. Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials. Arthritis Res Ther. 2013;15(1):6.  https://doi.org/10.1186/ar4134
  52. Foster CS, Vitale AT. Editors. Diagnosis and treatment of uveitis. Filadelphia. W B Saunders Company. 2002;900. 
  53. Levinson RD, Rosenbaum JT. Non steroidal Anti-inflammatory Drugs for prophylaxis of Acute Anterior Uveitis. Ocul Immunol and Inflamm. 2010; 18(2):69-71.  https://doi.org/10.3109/09273941003768224
  54. Wood SG, Fitzpatric K, Brodie R, Wright KU, Ellis ME. Pharmacokinetics and metabolism a new NSAID/analgesic aceclofenac in man. Pharm Res. 1990;7(9): 212. 
  55. Battle-Gualda E, Figueroa M, Ivorra J, Raber A. The efficacy and tolerability of aceclofenac in the treatment of patients with ankylosing spondylitis: a multicenter controlled clinical trial. Aceclofenac Indomethacin Study Group. J Rheumatol. 1996;23(7):1200-1206.
  56. Huskisson E, Irani M, Murray F. A large prospective open—label, multicentre SAMM study, comparing the safety of aceclofenac in patients with rheumatic disease. Eur J Rheumatol Inflamm. 2000;17:1-7. 
  57. Kroon FP, Van der Burg LR, Ramiro S, Laudewe RB, Buchbinder R, Falson L, Van der Heijde D. Nonsteroidal Antiinflammatory Drugs for axial Spondyloarthritis: A Cochrane Review. J Rheumatol. 2016;43(3):607-617.  https://doi.org/10.3899/jrheum.150721
  58. Savenkov MP, Brodskaya SF, Ivanov SN, Sudakova NI. The effect of non-steroidal anti-inflammatory drugs on the antihypertensive effect of ACE inhibitors. RMZ. 2003;19:1056-1059. (In Russ.).
  59. Angeli F, Trapasso M, Signorotti S, Verdeccia P, Reboldi G. Amlodipin and celecoxib for treatment of hypertension and osteoarthritis pain. Expert Rev Clin Pharmacol. 2018;11:1073. https://doi.org/10.1080/17512433.2018.1540299
  60. Polonia J. Interaction of antihypertensive drugs with anti-inflammatory drugs. Cardiology. 1997;88(3):47-51.  https://doi.org/10.1159/000177507
  61. Morgan T, Anderson A. The effect of nonsteroidal anti-inflammatory drugs on blood pressure in patients treated with different antihypertensive drugs. J. Clin Hypertens (Greenwith). 2003;5(1):53-57. 
  62. Garnier P, Hwang E. Meloxicam versus usual care NSAIDs for the treatment of osteoarthritis in the usual care setting. The results of the IMPROVE trial. Ann Rheum Dis. 2002;61(1):421. 
  63. Pelletier JP, Martel-Pelletier J. Effects of nimesulide and naproxen on the degradation and metalloprotease synthesis of human osteoarthritis cartilage. Drugs. 1993;43(1):34-39.  https://doi.org/10.2165/00003495-199300461-00008
  64. Rainsford K. Current status of the therapeutic uses and actions of the prefential cyclo-oxygenase-2NSAID, nimesulide. Inflammopharmacology. 2006;14: 120-137.  https://doi.org/10.1007/s10787-006-1505-9
  65. Conforti A, Leone R, Moretti U, Mozza E, Velo G. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from Northern Italian area. Drugs. 2001;24:1081-1090. https://doi.org/10.2165/00002018-200124140-00006
  66. Karateev AE, Alekseeva LI, Bratygina EA, Aschirova TB. Assessment of frequency of development of side effects at long use of a nimesulid in real clinical practice. Russkii Medicinskii Zhurnal. 2009;17(21):1466-1472. (In Russ.).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.